Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2022 | Bridging the gap between basic & clinical research to achieve personalized therapy in myeloma

Francesco Maura • 22 Aug 2022
IMS 2022
Multiple Myeloma

Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, talks on the importance of integrating advances in basic research into clinical trials for multiple myeloma and combining novel technologies together in order to provide personalized therapies to patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francesco Maura

Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more 13:45
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
Francesco Maura et al. • 24 Oct 2025
Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ? 1:49
Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ?
Francesco Maura • 19 Sep 2025
Genomic drivers of resistance to anti-BCMA immunotherapies in multiple myeloma 2:01
Genomic drivers of resistance to anti-BCMA immunotherapies in multiple myeloma
Francesco Maura • 19 Sep 2025
Genomic signatures to predict which patients with SMM and MGUS will progress 2:51
Genomic signatures to predict which patients with SMM and MGUS will progress
Francesco Maura • 19 Sep 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals